Tuesday, April 10, 2012

Social Media offerings at DIA2012

DIA 2012 Collaborate to Innovate
48th Annual Meeting
June 24-28, 2012
Philadelphia, PA
Pennsylvania Convention Center
                                                                                                                     
Title: The Impact of Social Media on Product Promotion and Pharmacovigilance
Social media creates challenges and opportunities for the promotion and safety of drugs and other medical products. FDA and industry are working to optimize truthful product information and ways to gather adverse event data utilizing this resource

Event Type: FORUM
Tracks: Advertising & Promotion|Regulatory Affairs|Medical Communications
Day: Monday, Jun, 25
Time: 10:00AM - 11:30AM
                                                                                                             

Presentation(s) & Speaker(s):
FDA Perspective
Thomas W. Abrams, MBA,RPh
Director, Office of Prescription Drug Promotion, CDER
FDA, United States

Panelist
Gerald J. Dal Pan, MD
Acting Director, Office of Surveillance and Epidemiology, CDER
FDA, United States

Industry Perspective
Paul James Savidge, JD,MBA
Vice President and Associate General Counsel
Bristol-Myers Squibb Company, United States

Industry Perspective
Elizabeth E. Garrard, PharmD,RPh
Chief Safety Officer
Drug Safety Alliance, Inc., United States


Title: AE Reporting in the Era of Web 2.0: The Challenges of Having a Two-Way Conversation
This session will focus on the specific types of social media currently being used by pharmaceutical companies with discussion on their successes and challenges. In addition, discussions on AE identification and collection while emphasizing the need for practices and guidance on the use of social media.
Event Type: FORUM
Tracks: Clinical Research|Medical Communications|Advertising & Promotion
Day: Monday, Jun, 25
Time: 1:30PM - 3:00PM


Presentation(s) & Speaker(s):Embracing and Incorporating New Technology (eg. Social media, iPad) into a Modern Pharmacovigilance System
Gregory J. Fiore, MD
President
SSI Strategy, United States

Safety and Social Media: Returning the Intention to Report: Adding the Human Factor Back to High Tech
Michael A. Ibara, PharmD
Head of Safety Innovation
Pfizer Inc, United States


Title: Social Media: The Promise and Pitfalls for Patient Recruitment
Social media has huge potential as a new set of tools to drive patient recruitment. How do you use it and what happens when you do? In this symposium, we will offer both successes and lessons learned from trying social media as a recruitment strategy.
Event Type: SYMPOSIUM
Tracks: Advertising & Promotion                                                                                
Day: Monday, Jun, 25
Time: 1:30PM - 3:00PM                                        


Presentation(s) & Speaker(s):Is Social Media the New Technology for Helping Patients Find Clinical Trials?
Richard Mayewski
Global Trial Optimization Specialist
Merck & Co., Inc., United States

Finding the “ePatient” for Your Clinical Trial
Rodney William Butt, MBA,MSc,MT
Principal Consultant, Clinical Operations
Hamilton Medical Consultants Group, Canada

When Social Media Undermines Clinical Trial Performance
Elizabeth A Moench
President and Chief Executive Officer
MediciGlobal, United States

                                               
Title: Communicating Drug Safety Information Using Social Media: FDA and Industry Perspectives
FDA relays the latest drug safety information through drug safety communications which are disseminated using social media tools. This session provides FDA and industry perspectives on the development, communication, dissemination, and impact of drug safety communications.

Event Type: SESSION
Tracks: Medical Communications|Clinical Safety/Pharmacovigilance|Regulatory Affairs
Day: Monday, Jun, 25
Time: 3:30PM - 5:00PM

Presentation(s) & Speaker(s):Communicating Drug Safety Information: FDA Perspective
Catherine Yu Chew, PharmD
Acting Deputy Director, Division of Drug Information, CDER
FDA, United States

Communicating Drug Safety Information :FDA Perspectives
Gregory Busse, PhD
Senior Writer/Editor, Team Lead for Drug Safety Communications, CDER
FDA, United States

Communicating Drug Safety Information: Industry Perspective
Sue E. James
Vice President, Global Regulatory and Quality, Consumer Healthcare
GlaxoSmithKline, United States

                              
Title: Social Media 2.0: The Power of Online Rare Disease Communities to Connect and Engage ePatients
Relevant case studies will be presented to demonstrate how online patient communities and social media are revolutionizing how patients gain access to disease and treatment information.
Event Type: FORUM
Tracks: Advertising & Promotion|Clinical Research
Day: Wednesday, Jun, 27
Time: 1:30PM - 3:00PM
Presentation(s) & Speaker(s):RareConnect: A Global Social Network for Rare Disease Communities and Patients
Mary Dunkle
Vice President of Communications
National Organization For Rare Disorders (NORD), United States

The Power of Patient-driven Research and Rare Disease Online Communities: The SCAD Ladies and Beyond
Brian Loew
CEO
Inspire, United States

Biopharma and Social Media: A Case Study
Eric Grinstead
Senior Vice President, Commercial Operations
Synageva Biopharma Corporation, United States

No comments:

Post a Comment